Shanghai Hengrui Pharmaceutical Co., Ltd.
The study was designed to evaluate the efficacy, safety, and pharmacokinetics of SHR2102 in patients with advanced solid tumors. The objective of this study was to determine the dose-limiting toxicity, maximum tolerance and recommended dose of SHR-A2102 in phase II study.
Advanced Solid Tumors
SHR-A2102
Phase 1
Study Type : | Interventional |
Estimated Enrollment : | 200 participants |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | An Open-Label, Single-Arm, Multi-Center Phase I Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of SHR-A2102 in Patients With Advanced Solid Tumors |
Actual Study Start Date : | April 6, 2023 |
Estimated Primary Completion Date : | August 31, 2025 |
Estimated Study Completion Date : | August 31, 2025 |
Arm | Intervention/treatment |
---|---|
Experimental: SHR-A2102 |
Drug: SHR-A2102 |
Ages Eligible for Study: | 18 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Recruiting
Shanghai Chest Hospital
Shanghai, Shanghai, China, 200030